Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.

VIEW PRODUCT PIPELINE

Advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression.

VIEW PRODUCT PIPELINE
About

We are a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders.

Read More

Product Pipeline


Preclinical
Phase 1
Phase 2
Phase 3
Approved

Azetukalner

for Focal Onset Seizures (FOS)
X-TOLE2/3 Clinical Trial

Azetukalner

for Primary Generalized Tonic-Clonic Seizures (PGTCS)​
X-ACKT Clinical Trial

Azetukalner

for Major Depressive Disorder (MDD)
X-NOVA Clinical trial

Azetukalner

for MDD
Investigator-led Phase 2 POC study Collaboration with Mount Sinai

Kv7

Potassium Channel Openers

Nav1.7

Sodium Channel Inhibitors

Nav1.1

Sodium Channel Openers

NBI-921352

for Rare Pediatric Epilepsy: SCN8A-DEE
Partnered with Neurocrine Biosciences


Investors

Visit our Investor page for News Releases, Annual & Quarterly Reports, Webcasts & Events

View Investor Area
Our Management

Learn more about Xenon's management group

View Management
Careers

See current career opportunities

View Careers